Volume 2 No. 3, July 2007

Can we predict the occurrence of mitral regurgitation during percutaneous balloon mitral valvuloplasty?

Mohamed Abdalaal¹, Hesham Elserogy²

Department of cardiology¹, clinical pathology², Faculty of Medicine, Tanta university hospital
Tanta Med. Sc. J 2007; 2(3):98-103
Article type: Original article

Background/Aim: mitral regurgitation is a frequent complication of percutaneous balloon mitral valvuloplasty. The creation of a new or an increase in preexisting one has been reported in 19 to 85% of patients undergoing percutaneous balloon mitral valvuloplasty. The aim of this work is to evaluate whether we can predict the occurrence of significant mitral regurgitation during percutaneous balloon mitral valvuloplasty with the use of C-reactive protein (CRP), erythrocytic sedimentation rate (ESR) and leucocytic count or not. Patients & Methods: 20 patients who developed significant mitral regurgitation during percutaneous balloon mitral valvuloplasty (group A) were retrospectively compared to another 20 age- and sex-matched control group (group B) who did not develop mitral regurgitation as regard CRP, ESR and leucocytic count.
Results: ESR, CRP and leucocytic count were found to be significantly higher in group A than in group B. Conclusion: higher levels of ESR, CRP and leucocytosis can predict the occurrence of significant mitral regurgitation in patients undergoing percutaneous balloon mitral valvuloplasty.